Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma

American Journal of Clinical Pathology

Volumn 129, Issue 2, 2008, Pages 245-251

  Buckley, Anne F ^a   Burgart, Lawrence J ^b   Sahai, Vaibhav ^c   Kakar, Sanjay ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Epidermal growth factor receptor; Fluorescence in situ hybridization; Hepatocellular carcinoma; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 7; CLINICAL FEATURE; DUPLICATE GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; GENETIC ASSOCIATION; GENETIC GAIN; HISTOPATHOLOGIC SKIN REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; CHILD; GENE DOSAGE; GENE EXPRESSION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PROTO ONCOGENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHILD; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 40449113855     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/WF10QAAED3PP93BH     Document Type: Article

References (41)

1. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update [published correction appears in Ann Intern Med. 2004;140:151]. Ann Intern Med. 2003;139:817-823.
2. Farmer DG, Rosove MH, Shaked A, et al. Current treatment modalities for hepatocellular carcinoma. Ann Surg. 1994;219:236-247.
3. Tanaka H. Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi. 1991;88:138-144.
4. Tang Z, Qin L, Wang X, et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl). 1998;111:313-318.
5. El-Bassiouni A, Nosseir M, Zoheiry M, et al. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006;114:420-427.
6. Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84:1377-1383.
7. Su Q, Liu Y. Expression of c-erbB-2 protein and EGF receptor in hepatitis B, cirrhosis and hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi. 1995;24:93-95.
8. Moon WS, Park HS, Yu KH, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol. 2006;37:1324-1332.
9. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
10. Mitchell P. Erbitux diagnostic latest adjunct to cancer therapy [published correction appears in Nat Biotechnol. 2004;22:760]. Nat Biotechnol. 2004;22:363-364.
11. Liu Y, Poon RTP, Shao W, et al. Blockage of epidermal growth factor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett. 2007; 248:32-40.
12. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005;41:307-314.
13. Hopfner M, Sutter A P, Huether A, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol. 2004;41:1008-1016.
14. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23:6657-6663.
15. Buckley A F, Burgart L, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37:410-414.
16. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signaling. Exp Cell Res. 2003;284:31-53.
17. Kari C, Chan TO, Rocha de Quadros M, et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 2003;63:1-5.
18. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(suppl 4):S9-S15.
19. Thoresen H, Guren T, Christoffersen T. Role of ERK, p38 and PI3-kinase in EGF receptor-mediated mitogenic signalling in cultured rat hepatocytes: requirement for sustained ERK activation. Cell Physiol Biochem. 2003;13:229-238.
20. Wang Y, Minoshima S, Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved FISH technique. Jpn J Hum Genet. 1993;38:399-406.
21. Marquez A, Wu R, Zhao J, et al. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol. 2004;13:1-8.
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
23. Alvarez G, Perry A, Tan BR, et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. 2006;19:942-949.
24. Kearsley JH, Leonard JH, Walsh MD, et al. A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology. 1991;23:189-194.
25. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol. 2001;193:476-482.
26. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7:31-39.
27. Zhao YN, Cao J, Wu FX, et al. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai Zheng. 2004; 23:762-766.
28. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver. 1999;19:318-325.
29. Kira S, Nakanishi T, Suemori S, et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver. 1997;17:177-182.
30. Hamazaki K, Yunoki Y, Tagashira H, et al. Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev. 1997;21:355-360.
31. Kannangai R, Sahin F, Torbenson S. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 2006;19:1456-1461.
32. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25:2164-2170.
33. Lynch TJ, Bell D W, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
34. Su MC, Lien HC, Jeng YM. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett. 2005;224:117-121.
35. Huether A, Hoepfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as a combination therapy for growth control of hepatocellular carcinoma. Biochem Pharmacol. 2005;70:1568-1578.
36. Huether A, Hoepfner M, Sutter A P, et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005;43:661-669.
37. Zhu B-D, Yuan S-J, Zhao Q-C et al. Antitumor effect of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with a cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol. 2005;11:1382-1386.
38. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.
39. Dei Tos A P, Ellis I. Assessing epidermal growth factor expression in tumors: what is the value of current test methods? Eur J Cancer. 2005;41:1383-1392.
40. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
41. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-286.